19-09-2021 | Oncology | News | Article
ARCHES reports enzalutamide OS benefit in men with mCSPC
The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.
14-07-2021 | Oncology | News | Article
MRI-based biopsy approach supported for prostate cancer screening
A population-based, screening-by-invitation trial has demonstrated that a combined MRI-guided plus standard biopsy approach is noninferior to standard biopsy with regard to the detection of clinically significant prostate cancer in men with increased prostate-specific antigen levels.
04-06-2021 | Oncology | News | Article
VISION: LuPSMA addition improves pretreated mCRPC survival
Supplementing standard of care treatment with lutetium-177-prostate-specific membrane antigen-617 significantly boosts the outcomes of heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, say the VISION investigators.
28-05-2021 | Oncology | News | Article
Olaparib role in mCRPC ‘may need to be reconsidered’
The benefit offered by olaparib in metastatic castration-resistant prostate cancer is attenuated when a more active standard of care is used as the comparator, suggests a network analysis of the PROfound and CARD trials.
Red heart with stethoscope on blue background/© denissimonov / stock.adobe.com, Treadmill workout/© .shock / Fotolia, Man in scanner/© emirkoo / Fotolia, Doctor and patient_3/© Syda Productions / Fotolia (Symbolic Image with Models)